.After increasing $170 thousand back in February, metabolic disease-focused BioAge Labs has submitted to debut on the general public market.The Eli Lilly-partnered biotech expect to list on the Nasdaq under the symbolic representation "BIOA," depending on to documentations filed with the Stocks as well as Substitution Commission. The company has not publicly discussed an expected monetary quantity for the offering.The clinical-stage business touts lead candidate azelaprag, a by mouth supplied little molecule slated to get into period 2 screening in combination with semaglutide-- offered by Novo Nordisk under trademark name Wegovy for weight reduction-- in the 1st fifty percent of next year. Semaglutide is actually also marketed as Ozempic and also Rybelsus by Novo for diabetes mellitus.
Apelin receptor agonist azelaprag is actually designed to blend well along with GLP-1 medications, boosting fat burning while protecting muscle mass. The investigational drug was found to become well-tolerated one of 265 people across 8 phase 1 tests, according to BioAge.Previously, BioAge amassed the support of Lilly to run a trial combining azelaprag along with the Big Pharma's GLP-1/ GIP receptor agonist tirzepatide, which is actually marketed for diabetes as Mounjaro and also Zepbound for fat burning. The companions are currently performing a stage 2 test of azelaprag and tirzepatide, with topline end results expected in the 3rd fourth of 2025.The biotech is likewise planning a blood insulin sensitivity proof-of-concept trial evaluating azelaprag as a monotherapy in the first fifty percent of following year to support potential sign growth. On top of that, the company prepares to ask the FDA for consent in the 2nd half of 2025 to launch individual testing for an NLRP3 inhibitor targeting metabolic illness as well as neuroinflammation.BioAge's anticipated move to the general public market follows a small uptick in prepared biotech IPOs from Bicara Rehabs as well as Zenas Biopharma. Zooming out, the recent IPO landscape is actually a "combined photo," with high quality providers still debuting on the general public markets, merely in lowered amounts, depending on to PitchBook.